Clinical Study

Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients

Table 4

Time course of biochemical paramters in cardiac transplant recipients on low-dose EVL (LD) or high-dose EVL (RD).

Parameter 𝑇 0 𝑇 6 𝑇 1 2 𝑃 value
LD 𝑛 = 5 1 ; RD 𝑛 = 5 6 LD 𝑛 = 4 4 ; RD 𝑛 = 4 1 LD 𝑛 = 3 9 ; RD 𝑛 = 3 6

Creatinine (mg/dL)
 LD group 2 . 2 3 ± 0 . 7 5 2 . 0 6 ± 0 . 8 7 2 . 0 5 ± 0 . 7 9 0.030
 RD group 2 . 0 6 ± 0 . 4 4 2 . 0 7 ± 0 . 8 3 2 . 0 8 ± 0 . 8 4 0.725
BUN (mg/dL)
 LD group 9 9 ± 3 8 8 1 ± 3 4 7 8 ± 2 9 0.003
 RD group 9 3 ± 3 7 9 7 ± 5 1 9 0 ± 4 1 0.420
Triglycerides (mg/dL)
 LD group 1 6 2 ± 8 0 1 9 8 ± 1 0 6 2 0 9 ± 1 1 6 0.006
 RD group 1 8 2 ± 1 0 7 2 5 4 ± 2 1 1 2 5 3 ± 2 2 2 0.063
Total cholesterol (mg/dL)
 LD group 2 0 6 ± 5 4 2 1 6 ± 6 2 2 2 2 ± 5 1 0.029
 RD group 1 9 9 ± 5 0 2 2 8 ± 6 3 2 2 9 ± 5 6 0.013
HDL-cholesterol (mg/dL)
 LD group 5 7 . 4 ± 1 5 . 7 5 7 . 0 ± 1 9 . 0 5 6 . 0 ± 1 6 . 6 0.639
 RD group 5 2 . 0 ± 1 5 . 7 5 9 . 4 ± 1 7 . 7 5 9 . 8 ± 1 5 . 4 <0.001
LDL-cholesterol (mg/dL)
 LD group 1 2 1 ± 4 5 1 2 5 ± 4 4 1 2 3 ± 4 1 0.815
 RD group 1 1 9 ± 3 3 1 2 9 ± 4 2 1 2 4 ± 4 3 0.611
White blood cells (106/L)
 LD group 7 . 5 8 ± 3 . 4 0 6 . 6 0 ± 1 . 8 9 6 . 3 6 ± 2 . 0 4 0.202
 RD group 7 . 2 3 ± 1 . 7 7 7 . 2 0 ± 1 . 5 7 7 . 1 1 ± 1 . 7 8 0.268
Red blood cells (1012/L)
 LD group 4 . 1 1 ± 0 . 6 1 4 . 3 2 ± 0 . 6 4 4 . 4 8 ± 0 . 7 4 <0.001
 RD group 4 . 1 5 ± 0 . 5 9 4 . 3 5 ± 0 . 6 9 4 . 4 4 ± 0 . 7 3 0.076
Platelets (109/L)
 LD group 2 1 8 ± 6 6 2 1 9 ± 6 5 2 2 0 ± 7 3 0.819
 RD group 2 2 3 ± 7 7 2 2 4 ± 5 9 2 2 0 ± 5 2 0.467